Here we set to investigate the role of CCND3 in the oncogenic program of other B-ALL subtypes, including BCR-ABL1+ B-ALL cell lines, which are distinguished by the highest CCND2 expression compared to other genotypes. This evidence concerns the gene CCND2 and acute lymphoblastic leukemia.